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Abstract
Advances in understanding the pathophysiology and mechanism of swelling in hereditary angioedema (HAE) has
resulted in the development of multiple new drugs for the acute and prophylactic treatment of patients with HAE.
This review will recap the past treatment options, review the new current treatment options, and discuss potential
future treatment options for patients with HAE.
Introduction
Hereditary angioedema with reduced C1 inhibitor func-
tion (HAE) is an autosomal dominant disease character-
ized by recurrent episodes of potentially life-threatening
angioedema. The pathophysiology of HAE as well as the
molecular mechanisms underlying attacks of swelling in
HAE have been gradually dissected over the past 50
years [1-3]. These advances have led to a rapidly chan-
ging set of therapeutic options for patients with HAE.
HAE patients typically begin to swell in childhood,
and often suffer increased symptoms about the time of
puberty, and continue to experience recurrent attacks of
angioedema throughout the remainder of their lives [4].
Attacks of angioedema in HAE can be severe and pro-
longed, typically lasting 3-5 days before the patient is
well again. Abdominal attacks may result in hospitaliza-
tion and all to often lead to inappropriate intra-abdom-
inal surgery, while oro-pharyngeal-laryngeal attacks can
be life-threatening [4-6]. Despite striking advances in
medical knowledge, HAE patients continue to die from
laryngeal attacks [7,8]. The disease thus imposes an
enormous burden on patients as well as their families,
often preventing them from leading a productive life.
Because of the significant morbidity and mortality
associated with HAE, careful management of these
patients is essential. The management of HAE required
attention to three areas: treatment of acute episodes of
angioedema, long-term prophylaxis, and short-term pro-
phylaxis [4,5,9,10]. To help the clinician navigate the
changing therapeutic landscape, this article will review
the past, current, and future options for treating HAE
patients in the United States.
HAE treatment: The past
Treatment of acute HAE attacks
Attacks of angioedema in patients with HAE involve
subcutaneous tissues (primarily involving extremities,
genitalia or the face), the intestine, and the respiratory
tract. Attacks typically but not invariably follow a trajec-
tory in which the angioedema increases for 24 hours
then slowly decreases over the following 48-72 hours.
Importantly, the swelling in HAE attacks does not
respond reliably to the drugs employed in treating other
forms of urticaria/angioedema such as anti-histamines,
epinephrine, or corticosteroids. While epinephrine, in
particular, may have a transient effect on swelling, it
does not alter the course of the attack.
Until late 2008, there was no drug approved in the
United States that was predictably effective for the treat-
ment of acute attacks of HAE. Anecdotal and published
experience suggests that administration of fresh frozen
plasma can abort ongoing HAE attacks by replacing
plasma C1 inhibitor (C1INH) levels [11]. There is, how-
ever, a theoretic and demonstrated risk that fresh frozen
plasma can worsen acute swelling, possibly due to
replenishment of plasma proteases and substrates
involved in the generation of peptides that mediate the
angioedema [12,13]. Epsilon aminocaproic acid (Ami-
car™) has also been used intravenously for acute epi-
sodes of angioedema, and anecdotal reports suggest that
it may be minimally helpful; however, there is no pub-
lished evidence demonstrating that it provides signifi-
cant benefit. Anabolic androgens, which are effective
prophylactic agents (see below) require at least 1-2 days
before they begin to be effective, and are therefore not
useful in the acute treatment of attacks.
The management of acute attacks was thus primarily
concerned with symptomatic control of the swelling.
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Abdominal attacks often present with severe pain and
nausea as well as significant dehydration, sometimes
accompanied by significant hypotension. Management of
these attacks involved aggressive intravenous replace-
ment of fluid as well as control of pain and nausea with
parenteral narcotic and antiemetic drugs. Oropharyngeal
attacks may lead to death secondary to asphyxiation,
and therefore required hospitalization for careful moni-
toring of airway patency. If the airway was threatened,
the patient needed to be intubated by an experienced
physician with the capability for emergency tracheotomy
immediately available. Acute angioedema of the extremi-
ties does not typically require treatment, although
angioedema of the feet or dominant hand can be tem-
porarily disabling.
Long-term prophylaxis
The goal of long-term prophylaxis is to decrease the fre-
quency and/or severity of swelling attacks. The fre-
quency and severity of angioedema attacks is highly
variable among HAE patients, ranging from attacks
occurring as often as twice per week to patients who are
asymptomatic. Most untreated HAE patients will swell
approximately one to two times per month on average.
While some HAE patients may not require long-term
prophylactic therapy, patients with frequent attacks or
with a history of serious attacks involving the upper air-
way should be treated prophylactically. In general
patients with significant swelling occurring more fre-
quently than once every 3 months are considered candi-
dates for long-term prophylactic therapy, although it is
the impact of the episodes on the patient’s ability to
lead a normal life that is the deciding factor. Other con-
siderations that should go into this decision include the
location of attacks (airway attacks causing increased
concern) and the accessibility of the patient to appropri-
ate medical care. Because of their ability to increase bra-
dykinin-mediated effects, angiotensin-converting enzyme
inhibitors need to be avoided in HAE patients. Birth
control pills and hormonal replacement therapy also fre-
quently exacerbate disease severity in women [14].
Two modalities of treatment were available for long-
term prophylaxis: anabolic androgens and anti-fibrinoly-
tics. The best tolerated and most effective long-term
prophylactic drugs are the synthetic anabolic androgens
which increase C1INH plasma levels and decrease
attacks of HAE [15]. The 17-a-alkylated androgens are
orally available and were the drugs of choice for the
long-term prophylaxis of HAE. Danazol and stanozolol
are synthetic 17-a-alkylated androgens that are widely
used for this purpose and are less virulizing than
methyltestosterone. Oxandrolone, a 17-a-alkylated
androgen that is approved for treatment of acquired
immunodeficiency syndrome wasting syndrome in chil-
dren, has also been successfully used to treat HAE [16].
The precise mechanism by which anabolic androgens
increase C1INH levels has not be elucidated [17]; but
the dose of anabolic androgen should not be based on
the C1INH response. The dose of anabolic androgens
used to treat HAE should be titrated down to find the
lowest dose which confers adequate prophylaxis, typi-
cally 2 mg stanozolol daily or every other day or 200 mg
danazol daily or every other day. Detailed recommenda-
tions for dose titration have been published [18].
The side effects of anabolic androgens are dose
related, with the most important side effects being hepa-
totoxicity and virulization [19]. Most HAE patients tol-
erate anabolic androgens at the doses described above,
however sustained use at higher doses often result in
significant side effects. Patients taking anabolic andro-
gens should have their liver enzymes checked every 6
months. Evidence of hepatic injury should precipitate
tapering or discontinuation of the drug, with documen-
tation of normalization of the hepatic tests. Since hepa-
tic adenomas have been reported as a consequence of
anabolic androgens [20], ultrasound examination of the
liver is warranted in the presence of persistently elevated
liver enzymes.
The antifibrinolytic drugs epsilon aminocaproic acid
(EACA or Amicar) and tranexamic acid are frequently but
not always effective in preventing angioedema attacks in
HAE [21-23]. The mechanism of their efficacy in HAE is
unknown. Because the anabolic androgens are more reli-
ably effective for the control of HAE, they were generally
used in preference to antifibrinolytics in adult patients
with the antifibrinolytic drugs often reserved for patients
who didn’t tolerate anabolic androgens. Because anabolic
androgens may interfere with normal sexual maturation,
antifibrinolytics have been preferred over androgens in
children and pregnant women. Tranexamic acid is not
currently available in the United States. The typical thera-
peutic dose of EACA is 1 gm orally 3-4 times per day.
The treatment of pregnant women and children pre-
sented particular difficulties. Androgens are contraindi-
cated in these populations due to their potential effects
on growth and sexual maturation. Angioedema fre-
quency may not change or may decrease during preg-
nancy; however, some women experience an increase in
attacks during pregnancy. Remarkably, almost all
women are protected from swelling during labor and
delivery.
Short-term prophylaxis
Short-term prophylaxis should be used to prevent
attacks of angioedema when the patient is at high risk
of swelling, particularly before expected trauma such as
surgery or dental procedures. To avoid potentially cata-
strophic swelling, it is critically important that all HAE
patients be made aware of the need for short-term pro-
phylaxis in these situations.
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High-dose anabolic androgen therapy (stanozolol 2 mg
three times daily or danazol 200 mg three times daily)
begun 5 to 7 days before the procedure affords reason-
able protection in most patients [18]. Alternatively, the
patient can be infused with two units of fresh frozen
plasma several hours before the procedure [24].
HAE treatment: The present
Over the past 18 months, 3 new medications for the
treatment of HAE have been approved for use in the
United States. Two of these medications are C1INH
concentrates and the third is a plasma kallikrein inhibi-
tor. Each of these is discussed below.
Plasma-derived C1INH concentrates
The pathophysiologic basis of HAE was demonstrated to
be a deficiency of C1INH in 1963 by Virginia Donaldson
[1], clarifying the lack of kallikrein inhibitory activity in
HAE patient plasma observed the year before by Land-
erman et al [25]. The rationale for replacement therapy
was established by the success of administering fresh
frozen plasma (FFP) during acute attacks of HAE [11].
Beginning in the late 1970s, a number of investigators in
Europe and the United States began demonstrating that
replacement therapy with C1INH concentrates was
effective in HAE.
Over the past 25 years, multiple studies have con-
firmed the efficacy of plasma C1INH as replacement
therapy for acute attacks of HAE [26-32]. Clinically,
symptomatic improvement is typically seen within 30-60
minutes of drug administration [33]. Furthermore,
C1INH concentrates appear to be equal efficacy for all
types of HAE attacks - including laryngeal attacks where
it can be life-saving [31]. C1 inhibitor concentrates have
also been successfully used for both short-term [34-37]
and long-term prophylactic treatment of HAE [38-40].
C1INH concentrate became the preferred modality of
treatment for acute attacks of HAE in some countries
where it is available.
In 1996, Waytes et al [41] published the results of two
double-blind placebo-controlled studies comparing
plasma derived C1INH (25 plasma units/kg; Immuno
AG) to placebo. The first was a crossover study invol-
ving prophylactic treatment of 6 severely affected HAE
patients who received study drug every three days. Dur-
ing the periods that they received C1INH, subjects
increased their plasma C1INH functional levels, normal-
ized their C4 titers and had significantly less swelling
than they did during the period they received placebo.
The second study assessed the time to improvement fol-
lowing study drug in 22 patients with acute attacks of
HAE. The beginning of relief occurred significantly fas-
ter in C1INH treated patients than in placebo treated
patients (55 versus 563 minutes). However, a pivotal
phase III trial of the Immuno C1INH concentrate
(Baxter Healthcare) for acute HAE attacks failed to
show any improvement in C1INH-treated compared to
placebo-treated subjects. Two plasma-derived C1INH
products underwent Phase 3 randomized clinical trials,
and were recently approved for use in the United States.
Pasteurized plasma-derived C1INH concentrate
Berinert (CSL Behring) is a pasteurized lyophilized
human plasma-derived C1 inhibitor concentrate for
intravenous injection. It has been licensed in Europe
(Germany, Austria, and Switzerland) for over 20 years,
and is also available in Canada. Numerous reports of
the efficacy and safety of Berinert have been published
(reviewed in [39]). A phase III study of Berinert for the
treatment of acute attacks of HAE was recently com-
pleted [42]. This study compared the efficacy (shorten-
ing onset of relief of symptoms) of 2 doses of Berinert
(10 U/kg and 20 U/kg) to placebo in 125 HAE patients
with moderate to severe abdominal or facial angioedema
attacks. Compared to the placebo treated group, subjects
receiving 20 U/kg of Berinert-P showed a significant
reduction in the median time to onset of relief of symp-
toms of HAE attacks compared to placebo (0.5 versus
1.5 hours, p = 0.0025). Median time to complete resolu-
tion of all HAE symptoms was also significantly shorter
in the 20 U/kg group compared to the control group
(4.92 versus 7.79 hours, p = 0.0237). At a dose of 10 U/kg,
the median time to onset of relief was 1.2 hours, which
was not significantly different than the placebo group.
Based on the data from this study, Berinert received
approval from the FDA for use in the treatment of
acute angioedema attacks in adolescent and adult HAE
patients.
Nanofiltered and pasteurized plasma-derived C1INH
concentrate
Cinryze (ViroPharma Incorporated) is a nanofiltered
pasteurized C1INH concentrate for intravenous use.
Cinryze is manufactured by Sanguin in the Netherlands,
using U.S. plasma. The manufacturing process is identi-
cal to that used for the existing Cetor C1INH product,
except that Cinryze is subjected to a final nanofiltration
step, which provides additional protection against envel-
oped and non-enveloped viral particles and possibly
prions [43]. Two separate randomized double-blind pla-
cebo controlled studies of Cinryze have been performed
in the United States [44].
The first study assessed efficacy and safety of C1INH-
nf for the treatment of moderate to severe acute attacks
of facial, abdominal or genitourinary angioedema in
HAE patients [45]. Subjects were infused with study
drug (C1INH-nf 1,000 IU or placebo) at time 0. If
significant relief was not reported within 60 minutes,
subjects were then given a second dose of the same
study drug they received initially. All subjects were
eligible to receive open-label Cinryze after 4 hours. In
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68 randomized eligible attacks, the estimated time to
beginning of unequivocal relief (primary endpoint) was
significantly shorter in the C1INH group (median
time 2 hours) than in the placebo group (median time
> 4 hours) (p = 0.026). Cinryze treated patients also
showed a statistically significant improvement in median
time to complete resolution of the defining symptoms
(p = 0.004). The efficacy of Cinryze treatment did not
vary by attack location.
A second study involved the use of C1INH-nf as long-
term prophylaxis to prevent attacks of angioedema was
also recently completed. Twenty-two patients with a his-
tory of frequent angioedema were treated with C1INH-
nf (1,000 IU) or placebo two times per week for 12
weeks then crossed over and received the other treat-
ment for an additional 12 weeks. During the C1INH-nf
treatment periods, subjects showed a highly significant
(p < 0.0001) decrease in HAE attacks (6.26 versus 12.73
attacks; p < 0.0001).
Cinryze received FDA approval for prophylactic treat-
ment in adolescent and adult HAE patients. The appli-
cation for use of Cinryze to treat acute attacks of
angioedema is still pending.
Safety and tolerability of plasma-derived C1INH
concentrates
Both Berinert and Cinryze are each derived from U.S.
plasma that has been PCR screened then subjected to
multiple viral inactivation/removal steps, including pas-
teurization. In addition, Cinryze undergoes nanofiltra-
tion, which removes viral- and potentially prion-sized
particles based on size exclusion rather than specific
physicochemical interactions. The results of the studies
described above did not show any evidence of safety or
tolerability issues with either of the drugs.
Plasma kallikrein inhibitor: ecallantide
Unraveling the mechanism of swelling in patients with
HAE has long been considered central to the develop-
ment of more effective treatment strategies. Early
investigations found that incubation of plasma from
HAE patients ex vivo at 37°C generated a factor that
caused smooth muscle contraction and increased vas-
cular permeability [46]. This ‘vascular permeability
enhancing factor ’ was correctly assumed to be the
mediator of swelling in HAE; however, the final char-
acterization of the factor remained elusive and contro-
versial for many years. Compelling laboratory and
clinical data have conclusively shown that bradykinin
is the primary mediator of swelling in HAE [47-57].
The nanopeptide bradykinin is generated when active
plasma kallikrein cleaves high molecular weight kinino-
gen (HMWK) [58]. The released bradykinin moiety
potently increases vascular permeability by binding to
its cognate receptor (the bradykinin B2 receptor) on
vascular endothelial cells.
The discovery that bradykinin is primarily responsible
for the attacks of swelling in HAE has led to new
therapeutic strategies to treat HAE by preventing brady-
kinin-mediated enhancement in vascular permeability.
Replacement therapy with C1INH will inhibit both
plasma kallikrein and activated factor XII. Indeed
administration of C1INH concentrate has been shown
to acutely reduce bradykinin levels in patients experien-
cing angioedema attacks [53]. Inhibition of plasma kal-
likrein using other non-C1INH drugs is another strategy
that has been used. The first plasma kallikrein inhibitor,
other than C1INH, to be used for the treatment of HAE
was aprotinin (Trasylol®). This protein is a broad-
spectrum Kunitz-type serpin inhibitor with activity
against trypsin, plasmin and plasma kallikrein. While
aprotinin was effective in halting acute attacks of HAE
[26,59], this bovine protein was associated with severe
anaphylactic reactions which precluded its use in HAE
management [60,61]. More recently, a specific plasma
kallikrein inhibitor, ecallantide, has been developed.
Ecallantide (Kalbitor, Dyax Inc.) is a novel, potent and
specific plasma kallikrein inhibitor produced in the
Pichia pastoris strain of yeast that was identified using
phage display technology for a library of rationally
designed variants of the first Kunitz domain of human
lipoprotein-associated coagulation inhibitor (LACI)
[62,63]. The recommended dose of ecallantide to treat
an angioedema attack is 30 mg, administered as three 1
ml subcutaneous injections. Maximum ecallantide levels
are reached 2-3 hours following subcutaneous injection,
and the half-life is approximately 2 hours [64].
Two separate RDBPC phase III studies of ecallantide
for the treatment of acute attacks of HAE have been
performed in the United States. Both studies involved
subjects randomized 1:1 to receive either ecallantide
30 mg or placebo by subcutaneous injection during a
moderate or worse attack at any location. The first trial
(EDEMA3) consisted of 72 patients with the primary
endpoint measured as a treatment outcome score (TOS)
at 4 hours. TOS is a patient-reported measure of
response to therapy using a categorical scale from 100
(significant improvement) to -100 (significant worsen-
ing) for each symptom complex, weighted according to
its baseline severity. Ecallantide-treated patients reported
a mean TOS score of 49.5 ± 59.4 compared to 18.5 ±
67.8 in placebo-treated patients (p = 0.037) [65]. The
improvement in TOS score was maintained at 24 hours
(44.3 ± 70.4 versus -0.5 ± 87.9, p = 0.044).
The second trial (EDEMA4) consisted of 96 patients
with the primary endpoint being mean symptom com-
plex severity (MSCS) at 4 hours. The MSCS score is a
patient-reported point-in-time measure of symptom
severity based on symptom rating of 0 (none) to 3
(severe) for each potential symptom complex. Severity at
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each time point is the average across all symptom com-
plexes. Ecallantide-treated subjects reported a mean
decrease in symptom score at 4 hours of 0.81 compared
to a decrease of 0.37 in placebo-treated subjects (p =
0.01). At 24 hours, mean symptom scores fell by 1.5 in
the ecallantide-treated subjects compared to 1.1 in the
placebo-treated subjects (p = 0.039).
No differences were observed in the response to
ecallantide based on the location of swelling; however
subjects who presented relatively late in the attack
(6-8 hours) showed less benefit than those who
presented earlier [66].
Safety is always paramount during drug development
and some concerns have arisen regarding the use of
ecallantide. Prolongation of the aPTT is commonly seen,
without any enhanced risk of bleeding. Anaphylactic-like
reactions have been reported in some subjects following
exposure to ecallantide, including one subject who
experienced a repeat reaction on re-challenge. A single
first dose anaphylactic-like reaction to ecallantide
described serum antibodies to a low molecular compo-
nent of the drug, detected by immunoblotting [67].
Controversy remains as no antibodies were detected by
ELISA screening performed by the manufacturer [68]. A
proportion of patients who receive repeated injections of
ecallantide will develop anti-drug antibodies. A relation-
ship between the presence of anti-drug antibodies and
risk of anaphylactoid reactions has yet to be observed,
and many of the antibody positive subjects have contin-
ued to use ecallantide with good results.
Based on data from both Phase III studies [69],
approval for use of ecallantide to treat acute HAE
attacks in patients aged 16 and over was granted on
December 2 2009. Because of the safety concerns
reviewed above, there is a black box warning on anaphy-
lactic potential and requiring that the drug be adminis-
tered by a health care provider.
Summary of current therapeutic options
The approval of Berinert, Cinryze and ecallantide has
completely changed the therapeutic options available for
the treatment of HAE in the United States. Berinert and
ecallantide are approved for treatment of acute attacks of
angioedema in HAE. These are the first drugs that are
reliably effective for the acute treatment of HAE attacks.
While it may be tempting to limit the use of these drugs
to severe or life-threatening attacks, it is clear that their
efficacy is highest when they are used early in an attack
when it is impossible to predict which attacks are likely
to become severe or life-threatening. In all likelihood,
therefore, these drugs will become the treatment of
choice for acute attacks of angioedema in HAE patients.
Long-term prophylaxis will still be important to limit the
number of attacks needing acute treatment.
Cinryze is approved for HAE prophylaxis rather than
acute treatment. In general, patients with relatively
severe (≥ 2 attacks per month) HAE are potential candi-
dates for prophylactic treatment with Cinryze. While
significantly better than placebo, routine prophylaxis
with Cinryze did not completely abrogate breakthrough
attacks, and it is likely that individualization of the
Cinryze dose or frequency of administration will be
necessary to achieve optimal responses in all treated
patients. It is also likely that low dose anabolic androgen
therapy will continue to be useful in patients who toler-
ate these drugs.
HAE treatment: The future
Two additional novel medications have undergone clini-
cal trials and are potentially in the pipeline for use to
treat acute attacks of angioedema in HAE patients.
Recombinant human C1INH
Rhucin (Pharming NV) is a recombinant human C1
inhibitor (rhC1INH) concentrate for intravenous infu-
sion isolated from the milk of transgenic rabbits. It is
identical to human plasma derived C1INH at the amino
acid level and demonstrates the same inhibitory profile
as plasma derived C1INH. However, rhC1INH has post-
translational glycosylation differences compared to the
plasma-derived product [70]. A phase I study of
rhC1INH in which the drug was administered to 12
asymptomatic HAE patients at doses ranging from 6.25
to 100 U/kg [71] demonstrated a rapid increase in func-
tional plasma C1INH activity and a corresponding fall
in C4 activation, followed by a slower increase in C4
levels. The half-life of the protein was dose dependent
and was longest at the highest dose used (100 U/kg)
where it was estimated to be 3 hours. The accelerated
clearance of rhC1INH from the plasma space compared
to plasma derived C1INH was presumably influenced by
the glycosylation differences in the recombinant protein.
An open-label phase II study of rhC1INH demonstrated
beginning of relief on average within 1 hour (median
time 30 minutes), with time to minimal symptoms on
average between 6 to 12 hours following infusion, and
no evidence of late angioedema relapses [72].
Two separate phase III studies have been performed
for rhC1INH in the treatment of acute attacks of
angioedema in HAE patients http://www.pharming.com.
A European randomized placebo-controlled double-
blind clinical study of rhC1INH (100 U/kg) in 32 HAE
patients was stopped on ethical grounds because of a
strong and highly significant positive advantage for
rhC1INH versus placebo in median time to beginning of
relief (62 versus 508 minutes, p = 0.0009) as well as
time to minimal symptoms (480 versus 1480 minutes,
p = 0.0038).
Zuraw Allergy, Asthma & Clinical Immunology 2010, 6:23
http://www.aacijournal.com/content/6/1/23
Page 5 of 8
The phase III study of rhC1INH (100 U/kg and 50 U/
kg) in the United States and Canada in 39 HAE subjects
showed a significant benefit for rhC1INH versus placebo
in median time to beginning of relief (68 minutes for
rhC1INH 100 U/kg, 122 minutes for rhC1INH 50 U/kg,
and 258 minutes for placebo). Time to minimal symp-
toms was also significantly shortened after treatment
with rhC1INH (245 minutes at 100 U/kg and 247 min-
utes at 50 U/kg) compared to placebo (1101 minutes).
There were no significant safety or tolerability issues
reported in these phase III studies. One subject in an
earlier phase study failed to report that she was allergic
to rabbits, and experienced hives and wheezing after
receiving rhC1INH
Icatibant
Another approach to treating HAE is by inhibiting the
ability of bradykinin to bind to and signal through its
cognate receptor, the bradykinin B2 receptor. In the
C1INH knockout mouse, blockade of the biologic action
of bradykinin using a bradykinin B2 receptor antagonist
abolished the increased vascular permeability and pro-
vided proof of concept that bradykinin was the mediator
of angioedema [57]. Lung et al [73] reported that HAE
clinical severity was influenced by a polymorphism in
the non-coding first exon of the bradykinin B2 receptor
that impacted bradykinin B2 receptor expression. A
recent report suggested that the permeability enhance-
ment in HAE attacks may be transduced by the combi-
nation of bradykinin B2 receptors and bradykinin B1
receptors [74]; and thus, bradykinin antagonists that
block both bradykinin receptors may have important
advantages to just blocking the bradykinin B2 receptor.
Icatibant (Firazyr, Shire) is a synthetic selective deca-
peptide bradykinin B2 receptor competitive antagonist
that contains five non-natural amino acids to enhance
resistance to peptidases [75,76]. Icatibant is administered
subcutaneously as a single 30 mg injection, achieves
peak concentration within 30 minutes, and has a half-
life of approximately 1-2 hours [77,78].
The safety and efficacy of icatibant for the treatment
of acute HAE attacks was assessed in two RDBPC phase
III studies [79]. One study compared icatibant to pla-
cebo in 56 subjects in the United States, Argentina, Aus-
tralia and Canada (FAST-1). The other study compared
icatibant to tranexamic acid in 72 subjects in Europe
and Israel (FAST-2). Both studies involved subjects ran-
domized 1:1 to receive either icatibant 30 mg by subcu-
taneous injection versus placebo (FAST1) or tranexamic
acid (FAST2) during a moderate to severe abdominal or
cutaneous angioedema attack. Primary endpoint was
time to onset of symptom relief assessed by subject-
recorded visual analog scale (VAS).
In the FAST-2 study, time to onset of relief was signif-
icantly faster in the icatibant treated subjects (2 versus
12 hours, p < 0.0001). Based on this, the drug was
approved for use for acute attacks in the European
Union. In contrast, the FAST-1 study failed to show a
significant benefit for icatibant (2.5 versus 4.6 hours, p =
0.13). The FDA disapproved the application for licen-
sure, and a new RDBPC phase III trial is ongoing.
Post-hoc analysis of the FAST-1 data suggests that
this study did not reach statistical significance due to
the confounding effect of narcotic pain relief given pri-
marily to placebo patients for abdominal attacks. Icati-
bant was generally well tolerated. The most common
side effect attributable to the drug was transient local
pain and swelling at the site of injection. Additional
attractive features of icatibant include its stability at
room temperature and a shelf life of at least one year.
Other future directions
Several additional treatment options will be briefly men-
tioned. First, the possibility of administering C1INH
concentrate by sub-cutaneous infusion is under active
consideration. This route may be ideal for obtaining
relatively steady plasma levels of C1INH during long-
term prophylaxis. Second, the possibility that coagula-
tion factor XII could become a therapeutic target. Like
strategies targeting plasma kallikrein, inhibition of factor
XII activity might prevent bradykinin generation [80].
Third, there is a possibility of developing orally available
bradykinin receptor antagonists. Fourth, the recent
demonstration that the bradykinin B1 receptor may play
a role in the swelling of HAE patients [74] suggests the
possibility of combined bradykinin B2 and B1 receptor
antagonism may be more effective than antagonizing the
bradykinin B2 receptor alone. Finally, advances in gene
repair or intracellular trafficking may eventually open
avenues for molecular correction of the defects in HAE.
Conclusion
The treatment of HAE, after remaining static for nearly
40 years, has undergone rapid change during the past
several years; and additional drugs are likely to be
approved within the next several years.
Since the time to complete resolution of an acute
attack is strongly influenced by the interval between
symptom onset and institution of effective therapy [81],
early self-treatment of acute attacks may provide the
best way to minimize morbidity from breakthrough
HAE attacks. The ease of use, stability and safety of ica-
tibant are positive attributes that enhance the likelihood
that it could be self-administered. While ecallantide is
also administered by the subcutaneous route, the restric-
tions requiring administration by a health care profes-
sional would preclude self administration at this time.
Variability in attack frequency and severity, response to
individual therapeutic agents, and the factors of gender,
age, pregnancy, co-existing medical conditions, or access
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to medical care highlight the need for individualization in
the approach to treatment of HAE. Ultimately, the intro-
duction of these drugs coupled with the availability of C1
inhibitor will allow for a menu of options to incorporate
into patient-centric treatment plans for HAE.
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